BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 31902694)

  • 41. Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia.
    Lugthart S; Gröschel S; Beverloo HB; Kayser S; Valk PJ; van Zelderen-Bhola SL; Jan Ossenkoppele G; Vellenga E; van den Berg-de Ruiter E; Schanz U; Verhoef G; Vandenberghe P; Ferrant A; Köhne CH; Pfreundschuh M; Horst HA; Koller E; von Lilienfeld-Toal M; Bentz M; Ganser A; Schlegelberger B; Jotterand M; Krauter J; Pabst T; Theobald M; Schlenk RF; Delwel R; Döhner K; Löwenberg B; Döhner H
    J Clin Oncol; 2010 Aug; 28(24):3890-8. PubMed ID: 20660833
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Three novel cytogenetically cryptic EVI1 rearrangements associated with increased EVI1 expression and poor prognosis identified in 27 acute myeloid leukemia cases.
    Haferlach C; Bacher U; Grossmann V; Schindela S; Zenger M; Kohlmann A; Kern W; Haferlach T; Schnittger S
    Genes Chromosomes Cancer; 2012 Dec; 51(12):1079-85. PubMed ID: 22887804
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Clinical and laboratory investigation of pericentric inv(9)(p22q34) with the der(9)t(9;22)(q34;q11) in Ph-positive leukemia].
    Fan Y; Ding SS; Pan JL; Xue YQ; Hu ZH
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2013 Apr; 30(2):157-60. PubMed ID: 23568725
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Successful treatment with
    Takeuchi A; Kondo T; Tasaka T; Yamada S; Hirose T; Fukuda H; Shimizu R; Matsuhashi Y; Kondo E; Wada H
    Leuk Res Rep; 2021; 15():100233. PubMed ID: 33376671
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Impact of an Additional Chromosome on the Clinical Outcomes of Hematopoietic Stem Cell Transplantation in Philadelphia Chromosome-Positive Acute Myeloid Leukemia in Adults.
    Min GJ; Kim HJ; Yoon JH; Kwak DH; Park SS; Jeon YW; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Min WS
    Biol Blood Marrow Transplant; 2018 Aug; 24(8):1621-1628. PubMed ID: 29698793
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Novel BCR-ABL1 fusion and leukemic mutations of SETBP1, PAX5, and TP53 detected by next generation sequencing in chronic myeloid leukemia.
    Fu S; Hu Y; Fu Y; Chen F; Liu X; Zhang M; Wang X; Tu S; Zhang J
    Cancer Biol Ther; 2016 Oct; 17(10):1003-1009. PubMed ID: 27611742
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Mechanisms of Resistance to ABL Kinase Inhibition in Chronic Myeloid Leukemia and the Development of Next Generation ABL Kinase Inhibitors.
    Patel AB; O'Hare T; Deininger MW
    Hematol Oncol Clin North Am; 2017 Aug; 31(4):589-612. PubMed ID: 28673390
    [TBL] [Abstract][Full Text] [Related]  

  • 48. BCR-ABL1 tyrosine kinase sustained MECOM expression in chronic myeloid leukaemia.
    Roy S; Jørgensen HG; Roy P; Abed El Baky M; Melo JV; Strathdee G; Holyoake TL; Bartholomew C
    Br J Haematol; 2012 May; 157(4):446-56. PubMed ID: 22372463
    [TBL] [Abstract][Full Text] [Related]  

  • 49. High reliability and sensitivity of the BCR/ABL1 D-FISH test for the detection of BCR/ABL rearrangements.
    Pelz AF; Kröning H; Franke A; Wieacker P; Stumm M
    Ann Hematol; 2002 Mar; 81(3):147-53. PubMed ID: 11904740
    [TBL] [Abstract][Full Text] [Related]  

  • 50. H2AFY is a novel fusion partner of MECOM in acute myeloid leukemia.
    Han Q; Lu J; Wang J; Ye J; Jiang X; Chen H; Liu C; Chen L; Lin T; Chen S; Sun M; Gao F
    Cancer Genet; 2018 Apr; 222-223():9-12. PubMed ID: 29666008
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Both AML1 and EVI1 oncogenic components are required for the cooperation of AML1/MDS1/EVI1 with BCR/ABL in the induction of acute myelogenous leukemia in mice.
    Cuenco GM; Ren R
    Oncogene; 2004 Jan; 23(2):569-79. PubMed ID: 14724585
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors.
    Pietarinen PO; Eide CA; Ayuda-Durán P; Potdar S; Kuusanmäki H; Andersson EI; Mpindi JP; Pemovska T; Kontro M; Heckman CA; Kallioniemi O; Wennerberg K; Hjorth-Hansen H; Druker BJ; Enserink JM; Tyner JW; Mustjoki S; Porkka K
    Oncotarget; 2017 Apr; 8(14):22606-22615. PubMed ID: 28186983
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Aberrant EVI1 splicing contributes to EVI1-rearranged leukemia.
    Tanaka A; Nakano TA; Nomura M; Yamazaki H; Bewersdorf JP; Mulet-Lazaro R; Hogg S; Liu B; Penson A; Yokoyama A; Zang W; Havermans M; Koizumi M; Hayashi Y; Cho H; Kanai A; Lee SC; Xiao M; Koike Y; Zhang Y; Fukumoto M; Aoyama Y; Konuma T; Kunimoto H; Inaba T; Nakajima H; Honda H; Kawamoto H; Delwel R; Abdel-Wahab O; Inoue D
    Blood; 2022 Aug; 140(8):875-888. PubMed ID: 35709354
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Long-term remission of therapy-related acute myeloid leukemia with a new t(11;18)(q23;q21.2) translocation and KMT2A-ME2 (MLL-ME2) fusion gene.
    Szotkowski T; Jarošová M; Zimmermannová O; Meyer C; Marschalek R; Zuna J; Hubáček J; Indrák K
    Cancer Genet; 2015 Dec; 208(12):610-4. PubMed ID: 26556690
    [TBL] [Abstract][Full Text] [Related]  

  • 55. MLL Rearrangment and EVI1 Deletion in BCR/ABL1 Positive Chronic Myeloid Leukemia.
    Ivanov A; Sukhanova M; Raul T; Borinets O; Hui W; Aggarwal V; Raca G
    J Assoc Genet Technol; 2013; 39(4):190-4. PubMed ID: 26030291
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Recommendations from the French CML Study Group (Fi-LMC) for BCR-ABL1 kinase domain mutation analysis in chronic myeloid leukemia].
    Cayuela JM; Chomel JC; Coiteux V; Dulucq S; Escoffre-Barbe M; Etancelin P; Etienne G; Hayette S; Millot F; Nibourel O; Nicolini FE; Réa D;
    Bull Cancer; 2020 Jan; 107(1):113-128. PubMed ID: 31353136
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Does BCR/ABL1 positive acute myeloid leukaemia exist?
    Nacheva EP; Grace CD; Brazma D; Gancheva K; Howard-Reeves J; Rai L; Gale RE; Linch DC; Hills RK; Russell N; Burnett AK; Kottaridis PD
    Br J Haematol; 2013 May; 161(4):541-50. PubMed ID: 23521501
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The New Clinicopathologic and Molecular Findings in Myeloid Neoplasms With inv(3)(q21q26)/t(3;3)(q21;q26.2).
    Wang HY; Rashidi HH
    Arch Pathol Lab Med; 2016 Dec; 140(12):1404-1410. PubMed ID: 27628325
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Quantitative BCR-ABL1 RQ-PCR fusion transcript monitoring in chronic myelogenous leukemia.
    Moore FR; Rempfer CB; Press RD
    Methods Mol Biol; 2013; 999():1-23. PubMed ID: 23666687
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Mutations in the BCR-ABL1 Kinase Domain and Elsewhere in Chronic Myeloid Leukemia.
    Soverini S; de Benedittis C; Mancini M; Martinelli G
    Clin Lymphoma Myeloma Leuk; 2015 Jun; 15 Suppl():S120-8. PubMed ID: 26297264
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.